February 21, 2023 — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that the Final Determination ruling issued by the U.S. International Trade Commission (ITC), which imposed a Limited Exclusion Order (LEO) and a cease and desist order on Apple Watches infringing on AliveCor patents, has cleared Presidential review. This is the Commission’s first LEO against Appleto clear Presidential review, and sends a strong signal to innovative companies that their IP is protected within the legal framework.
The ITC’s ruling in December affirmed that Apple infringed AliveCor’s groundbreaking intellectual property. The LEO will go into effect upon favorable resolution of appeals in the case, including AliveCor’s appeal of the U.S. Patent Trial and Appeal Board’s decision.
“We applaud President Biden for upholding the ITC's ruling and holding Apple accountable for infringing the patents that underpin our industry-leading ECG technology,” said Priya Abani, CEO of AliveCor. “This decision goes beyond AliveCor and sends a clear message to innovators that the US will protect patents to build and scale new technologies that benefit consumers.”
Beyond the successful patent infringement ruling with the ITC, AliveCor continues to hold Apple accountable for its anticompetitive behavior through its antitrust case in the Northern District of California, which is expected to go to trial in early 2024.
For more information: www.alivecor.com
Related Wearable ECG Monitoring Content:
ITC Rules Apple Violated AliveCor’s Patents
How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience
Cardea Solo Wearable ECG Collects High-altitude Cardiac Data on Denali Expedition
Cardiac Insight Partners With VivoSense for Cardiovascular Research
Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation
As Interpretation Criteria Evolve, False Positive Athlete ECG Screening Rates Can Decrease
January 23, 2024 
